US Capitol Capsule: Swimming the political sea with the FDA: A fine kettle of fish?
This article was originally published in Scrip
Executive Summary
What played out on Capitol Hill in the aftermath of the September 2004 withdrawal from the worldwide market of Merck's Vioxx (rofecoxib) – with regulators being frequently hauled in front of congressional committees – is probably the best evidence the US FDA is often at the mercy of political and societal pressures.